Connect with us

Health

FDA warns that nicotine-like chemicals in vapes may be more potent than nicotine

Published

on

FDA warns that nicotine-like chemicals in vapes may be more potent than nicotine
  • Nicotine alternatives like 6-methyl nicotine in vapes may be more addictive than nicotine, according to the FDA.
  • These synthetic substances are not regulated by U.S. tobacco and vaping laws that control traditional nicotine.
  • Traditional nicotine is derived from tobacco leaves, while 6-methyl nicotine is synthesized in labs using chemicals.

Nicotine alternatives used in vapes being launched in the U.S. and abroad, such as 6-methyl nicotine, may be more potent and addictive than nicotine itself, though the scientific data remains incomplete, according to the U.S. Food and Drug Administration (FDA) and independent researchers.

The synthetic substances – which have a chemical structure similar to that of nicotine – are not subject to U.S. tobacco and vaping regulations that are designed to control traditional nicotine, a highly addictive drug.

That means manufacturers can sell vapes containing synthetic nicotine analogues such as 6-methyl nicotine in the United States without seeking authorization from the FDA – a process that can be costly, time-consuming and is often unsuccessful.

YOUNG VAPER WHO REQUIRED DOUBLE LUNG TRANSPLANT SHARES WARNINGS AS E-CIGARETTE SALES RISE

Big tobacco firms like Altria Group and British American Tobacco have already lost substantial U.S. sales to an influx of disposable vapes containing traditional nicotine that are being illegally sold without FDA authorization.

Various vapes, nicotine products and the new Spree Bar, which contains a chemical that mimics nicotine, line the shelves at Sultans’ Smoke in Arvada, Colorado, on May 21, 2024. (REUTERS/Kevin Mohatt/ File Photo)

Advertisement

Altria, the maker of Marlboro cigarettes in the United States, highlighted the emerging use of 6-methyl nicotine in vapes and other smoking alternatives in a May 9 letter to the FDA, according to a copy of the correspondence posted on its website.

It urged the agency to evaluate the compounds and establish what authority it had over them, warning they posed a “new threat” to regulation of the sector.

“The introduction and growth of chemicals intended to imitate the effects of nicotine, if left unchecked, could present unknown risks to U.S. consumers and undermine FDA’s authority,” the letter said.

SMOKING CIGARETTES CAN DESTROY LUNGS, BUT SHOCKING NEW STUDY REVEALS WHY VAPING CAN HARM THE HEART

It cited SPREE BAR, a vape launched in October by Charlie’s Holdings Inc that uses 6-methyl nicotine.

Advertisement

The FDA does not comment on its correspondence with individual firms.

In response to Reuters’ questions about 6-methyl nicotine and other nicotine alternatives, the FDA said in a statement: “Although more research is needed, some emerging data show these nicotine analogs may be more potent than nicotine – which is already highly addictive, can alter adolescent brain development and have long-term effects on youth’s attention, learning and memory.”

Traditional nicotine found in many vapes and pouches is extracted from tobacco leaves. 6-methyl nicotine, in contrast, is made entirely in the lab using chemicals.

The FDA said it was considering the use of such synthetic compounds from an “agency-wide perspective” and would use all of its resources to protect youth from products that may harm their health. As well as tobacco products, the FDA also regulates drugs, foods, cosmetics and more to ensure safety and efficacy.

“The FDA is a data-driven agency, and we’re in the process of reviewing the available data to inform potential actions in this space,” it said in response to Reuters’ questions.

Advertisement

Three academic researchers told the news agency that current studies of 6-methyl nicotine are too limited to draw definite conclusions on the health impact or to what degree it is addictive.

Imad Damaj, a professor in the Department of Pharmacology and Toxicology at Virginia Commonwealth University, said his research showed 6-methyl nicotine may be more potent than nicotine, but more extensive tests were needed to say what impact it has on humans.

The limitations of existing research included that some papers were industry funded, while others focused on the short-term impact on animals or cells and were insufficient to understand 6-methyl nicotine’s effects on human bodies, the researchers said.

Charlie’s Holdings calls the 6-methyl nicotine solution used in SPREE BAR Metatine. SPREE BAR’s website says Metatine “may have a toxicity profile similar to nicotine”.

SPREE BAR promises users 6,000 puffs from each device and offers fruity flavors including “blue razz ice” and “creamy melon”, according to its website.

Advertisement

The FDA has yet to approve any flavored vape using traditional nicotine for sale in the United States, saying companies have not been able to show that the health benefits they offer to smokers outweigh the known risks to young people, who may be more attracted by the flavors.

Charlie’s Holdings co-founder Ryan Stump told Reuters that the company only targets adults, adding that flavors played an important role in its mission to help smokers quit cigarettes.

Stump said Charlie’s Holdings respects and abides by laws in every market where it operates. He acknowledged that more research is needed on 6-methyl nicotine, adding that the company dilutes it in its products.

US SCHOOLS INVEST MILLIONS IN SURVEILLANCE TECHNOLOGY TO COMBAT TEEN VAPING EPIDEMIC

TARGETING INTERNATIONAL MARKETS

Anes Saleh sells SPREE BAR in his vape shop in Denver, Colorado, called Sultan Smoke. He said he has some customers who only buy Spree Bar instead of a nicotine vape and he hasn’t had any negative feedback on the product.

Advertisement

“The only… protest I would hear about people not wanting to try this is that they don’t know what Metatine is or does,” he said.

Stump said that Charlie’s Holdings is working on new varieties of SPREE BAR and new products using 6-methyl nicotine. It will launch SPREE BAR internationally this year. He declined to say where.

The company buys the 6-methyl nicotine solution used in SPREE BAR from another U.S. firm, Novel Compounds, according to Novel Compounds’ founder Samuel Benaim.

Novel Compounds imports 6-methyl nicotine from overseas and alters it to make it easier for manufacturers like Charlie’s Holdings to use in their products. It sells this solution under the trade name imotine.

Tests commissioned by Novel Compounds have found 6-methyl nicotine to be no more harmful than nicotine, Benaim said. But he also said that more research was needed into the chemical.

Advertisement

Benaim added that Novel Compounds had received legal advice that its product is not classified as a tobacco product or drug in the United States. The company is committed to legal compliance, he said.

MORE POTENT THAN NICOTINE?

Sven Jordt, a professor at Duke University, who has authored papers on products like SPREE BAR, said 6-methyl nicotine could me more addictive and toxic than its traditional cousin.

“Do we want to have such a chemical as a recreational product, available to anyone?,” he asked. “That’s really questionable.”

Neither Jordt nor Damaj – the professor at Virginia Commonwealth University – have received funding from tobacco or vape makers.

As well as the United States, Novel Compounds also sells its 6-methyl nicotine solution around the world, including in the United Kingdom, Indonesia, India and Japan.

Advertisement

Another company, Aroma King, sells 6-methyl nicotine in the United Kingdom in pouches, which users insert under the lip to get a buzz. The pouches are sold in cans emblazoned with graphics of gorillas in suits and sunglasses.

It said in a February blog post that its 6-methyl nicotine products were “less toxic”, “less harmful”, and “less addictive” than regular nicotine products.

In a statement to Reuters, Aroma King cited existing research, its own toxicology and other tests and its supplier, which classifies 6-methyl nicotine as less toxic under the European Union’s Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation.

Aroma King said 6-methyl nicotine was self-classified by its supplier. It declined to say who supplies it with the chemical.

Advertisement

Four Chinese companies hold patents in China related to the production of 6-methyl nicotine, including Zinwi Biotech, a company that makes the liquid used in vapes.

Zinwi Biotech confirmed it is researching 6-methyl nicotine but did not answer further questions, including on whether it has sold any 6-methyl nicotine so far. Reuters was unable to find contact details for the other firms.

Health

Big Medicare change slashes weight-loss drug costs for eligible seniors

Published

on

Big Medicare change slashes weight-loss drug costs for eligible seniors

NEWYou can now listen to Fox News articles!

Millions of Medicare beneficiaries struggling with obesity could soon see the cost of weight-loss drugs plummet, as a new federal pilot program launching July 1 expands access to GLP-1 medications like Wegovy and Zepbound for eligible seniors.

Advertisement

Through a new trial called Medicare GLP-1 Bridge, the federal government is now offering a selection of the brand-name medications to certain Medicare and Medicare Advantage beneficiaries for $50 a month, The Associated Press reported.

The covered medications include drugmaker Eli Lilly’s Foundayo tablets and Zepbound KwikPens and Novo Nordisk’s Wegovy injections and tablets, all of which have been FDA-approved for weight loss, according to the report.

OZEMPIC USERS MAY BE MAKING A MAJOR WEIGHT-LOSS MISTAKE, NEW STUDY SUGGESTS

The temporary program is set to run until the end of 2027.

This is the first time GLP-1s (glucagon-like peptide-1 receptor agonists) will be covered by insurance when used solely for weight loss.

Advertisement

A new federal pilot program launching July 1 expands access to GLP-1 medications like Wegovy and Zepbound for eligible seniors. (iStock)

Prior to this new Medicare pilot, seniors who wanted to access GLP-1s for obesity alone paid about $1,350-$1,650 per month for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 monthly for Lilly’s Zepbound (tirzepatide). However, both manufacturers offered some cash-pay options that significantly reduced those prices for eligible patients.

GLP-1 WEIGHT LOSS DRUGS ARE RESHAPING THE BRIDAL INDUSTRY AS SHOPS RUSH ORDERS AND REQUIRE NEW WAIVERS

There are some parameters surrounding the coverage — older adults must have had a body mass index (BMI) of 35 or higher when they started GLP-1 therapy, or a BMI of 27 or higher alongside another health condition, such as a past heart attack or stroke or prediabetes.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

Those who already have insurance coverage for other diseases, such as diabetes and sleep apnea, are not eligible for the program.

Through a new trial called Medicare GLP-1 Bridge, the federal government is now offering a selection of the brand-name medications to certain Medicare and Medicare Advantage beneficiaries for $50 a month. (iStock)

There are more than 70 million Americans currently enrolled in Medicare, 10 million of whom are overweight or obese, according to Juliette Cubanski, vice president and director of the program on Medicare policy at the healthcare research nonprofit KFF.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“For many older Americans living with obesity, this is a moment they and their families have been waiting for,” Jamey Millar, Novo Nordisk’s executive vice president of U.S. operations, said in a press release.

Advertisement

“The Medicare GLP-1 Bridge program offers a new, affordable path to an FDA-approved treatment that was previously not covered.”

CLICK HERE FOR MORE HEALTH STORIES

Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, said he hopes the program can help his agency collect data to potentially work toward longer-term coverage, while providing immediate relief to cash-strapped older Americans, AP reported.

“The sheer cost of these medications is a huge barrier to access,” he said in a call with reporters. “That ends today.”

Prior to this new Medicare pilot, seniors who wanted to access GLP-1s for obesity alone paid about $1,350-$1,650 per month for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 monthly for Lilly’s Zepbound (tirzepatide).  (iStock)

Advertisement

Oz told reporters that CMS plans to “carefully track participation and outcomes” to see whether an extension of the Bridge program or another solution is the best way to move forward. He told AP a federal law permanently allowing the coverage is “not essential right now” but something “for Congress to debate amongst themselves.”

“We can’t decide what’s going to happen long term with Bridge until we see some of the data,” he said, adding that there are ongoing talks with drug companies to lower costs.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

One potential concern is that older patients tend to have more adverse effects to medication in general , according to Dr. Micah Eimer, a clinical assistant professor of cardiology at the Northwestern University Feinberg School of Medicine.

“Specifically, in our research, older patients on blood pressure medications were more likely to experience hypotensive side effects, such as fainting and dizziness, after starting a GLP-1,” he said in a statement.

Advertisement

The Associated Press contributed to this report.

Continue Reading

Health

She Ate High-Protein Ice Cream Daily and Lost 193 Lbs—Her Keys to Success

Published

on

She Ate High-Protein Ice Cream Daily and Lost 193 Lbs—Her Keys to Success


Advertisement





High-Protein Ice Cream and Carb Cycling Helped Her Lose Weight Fast




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Mystery parasite leaves Americans battling ‘explosive’ illness as CDC investigates

Published

on

Mystery parasite leaves Americans battling ‘explosive’ illness as CDC investigates

NEWYou can now listen to Fox News articles!

Federal health officials are attempting to track down the source of a microscopic parasite that triggers prolonged gastrointestinal illness, as domestic cases begin to climb for the summer season.

The Centers for Disease Control and Prevention had confirmed 145 cases of cyclosporiasis across 17 states as of mid-June 2026, all linked to infections acquired in the U.S.

The culprit is Cyclospora, a microscopic parasite known to cause cyclosporiasis.

DEADLY ‘FOX TAPEWORM’ LINKED TO LETHAL DISEASE DETECTED IN WEST COAST WILDLIFE

Advertisement

The hallmark symptom of the infection is watery, often “explosive” diarrhea that can last for weeks or even months if left untreated, the CDC says.

There is currently no evidence of a single, multistate Cyclospora outbreak linking all cases. (AP Photo/Jeff Amy, File)

Other symptoms include severe abdominal cramping, bloating, nausea, fatigue and significant weight loss.

The official outbreak season for the parasite runs from May 1 through Aug. 31, a window where warmer temperatures historically coincide with a spike in infections, according to the CDC.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Advertisement

Cases have cropped up in states ranging from Texas to Alaska. New York has been hit the hardest so far, reporting between 31 and 80 cases, followed by Texas and Illinois, which have each reported between 11 and 30 cases.

CLICK HERE FOR MORE HEALTH STORIES

While the infection can sometimes clear up on its own, it frequently requires antibiotics. Out of the 145 confirmed cases, 20 patients have required hospitalization, per the CDC.

While the infection can sometimes clear up on its own, it frequently requires antibiotics. (iStock)

No deaths have yet been reported. Patients range from 5 to 86 years old, though the median age is 42, and women make up 61% of the reported cases, data shows.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The CDC, alongside the Food and Drug Administration and state health officials, is actively investigating several multi-state clusters, but they have yet to find a cause behind the spread.

Officials urge patients with symptoms to seek help from a medical professional. (iStock)

“There is currently no evidence of a single, multistate Cyclospora outbreak linking all cases,” the CDC noted in its surveillance report.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

The CDC advises anyone experiencing symptoms of cyclosporiasis to contact a healthcare provider for testing and treatment.

Continue Reading
Advertisement

Trending